AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Suda pharmaceuticals ltd asx sud
SUDA Announces $3.56 Million Capital Raising to Fund Development of its Key Assets
July 06, 2020 11:28 AM AEST| By Team Kalkine MediaAustralia’s oro-mucosal drug delivery leader, SUDA Pharmaceuticals Limited (ASX:SUD) has recently announced a non-renounceable entitlement offer to raise about $3.56 million via issue of ~142 million new ordinary shares in SUDA, at an attract.....
SUDA Reports Significant Preliminary Results from Anagrelide Pharmacokinetic Study
May 28, 2020 05:07 PM AEST| By Team Kalkine MediaSummary SUDA made further progress towards Anagrelide program, attaining significant preliminary results from a pharmacokinetic study. Results support SUDA’s hypothesis that Anagrelide’s mouth spray formulation can lessen the risk o.....
Japanese Patent Office Accepted SUDA’s Anagrelide Cancer Patent Application; Stock Surged Over 10%
May 21, 2020 12:29 PM AEST| By Team Kalkine MediaThe Japanese Patent Office has accepted Anagrelide cancer patent application, and the patent would now proceed to grant, notified SUDA Pharmaceuticals Ltd (ASX:SUD) in its latest update. The patent “Use of Anagrelide for Treating Cancer”...
SUDA Expects TGA Review Completion for ZolpiMist™ by Q4 2020
May 14, 2020 12:52 PM AEST| By Team Kalkine MediaSUDA Pharmaceuticals Limited (ASX:SUD), an Australia-based oro-mucosal drug delivery player, notified in its latest update that the Therapeutic Goods Administration (TGA) review for its insomnia drug ZolpiMistTM is expected to be completed by Q4 2020...
SUDA’s March Quarter Report Card Out! Let’s Browse Through Key Developments
May 04, 2020 11:55 AM AEST| By Team Kalkine MediaOro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) has announced another set of robust quarterly results for the third quarter of FY2020. During the period, the Company made considerable progress in line with the 2020 targets h...
SUDA Pharmaceuticals Discovering Use of Anagrelide as Adjuvant Therapy in Treating Cancer
April 17, 2020 03:03 PM AEST| By Team Kalkine MediaPills, capsules, and tablets may not be the most efficient method for administering medicines as only ~10 – 30 per cent of the drug reaches the bloodstream. Several factors, including food effect, enzymatic degradation and first-pass metabolism...
SUDA Sets Out Steps in Response to COVID-19 Pandemic
April 01, 2020 04:03 PM AEDT| By Team Kalkine MediaIn a recent letter to its top shareholders, Perth-based oro-mucosal drug delivery company SUDA Pharmaceuticals Ltd (ASX:SUD) has outlined the steps it is taking amidst COVID-19 pandemic, that has so far infected more than 780,000 people and claimed l...
SUDA Continues With its Commercial Buildout of ZolpiMist™, Signed Additional Licence for the product with Mitsubishi Tanabe Pharma Korea
March 24, 2020 08:40 PM AEDT| By Team Kalkine MediaProgressing remarkably with the commercialisation of its insomnia drug ZolpiMistTM, the oro-mucosal drug delivery leader SUDA Pharmaceuticals Limited (ASX:SUD) has signed an additional licence agreement with one of the top Japanese pharmaceutical com...
SUDA Delivered Strong Performance in 2Q FY20, A Glimpse of Operational Highlights
February 05, 2020 02:23 PM AEDT| By Team Kalkine MediaContinuing its practice of making robust quarterly progress, the oro-mucosal drug delivery player of Australia, SUDA Pharmaceuticals Limited (ASX: SUD) is out with another solid quarterly report for the December 2019 quarter. SUDA is a world leader...
SUDA Makes Speedy Progress with its Robust Product Pipeline
August 21, 2019 01:28 PM AEST| By Team Kalkine MediaSUDA Pharmaceuticals Ltd (ASX: SUD) is transforming the drug delivery technology to improve the lifestyle and health of the global community by offering innovative and high-quality oro-mucosal spray pharmaceutical products to aid in the treatment of...
SUDA’s Science Advisory Board Member, Dr Richard Franklin Joins as Project Director of Anagrelide Project
August 14, 2019 12:51 PM AEST| By Team Kalkine MediaSUDA Pharmaceuticals Ltd (ASX: SUD), an oro-mucosal drug delivery company headquartered in Perth, focusses on developing low-risk oral sprays using its proprietary OroMist? oro-mucosal technology to reformulate the existing medications. The OroMist?...
Suda Pharmaceuticals Is All Set To Commercialize SUD-001H
November 08, 2018 08:43 AM AEDT| By Team Kalkine MediaSuda Pharmaceuticals Limited (ASX:SUD) announced regarding its entry into an?exclusive product development, licence and supply agreement with the fully owned subsidiary of Strides Pharma Science Ltd, Strides Pharma Global Pte Ltd on November 8, 2018....
Advertise your brand on Kalkine Media